Billionaire Philippe Laffont Trimmed: Two Big Moves
When a renowned investor rebalances a multibillion-dollar portfolio, the moves ripple through markets. This piece exp...
What Should Your Retirement Savings Goal Be At 30
Determining your retirement savings goal at 30 is crucial for financial stability. Learn what you should aim for to secure your retirement.
25,114 articlesEx-Disney Star Hilary Duff Warns: Saying Yes Can Backfire
In a candid reflection, ex-disney star hilary duff explains how constant agreement with opportunities can undermine l...
The Imminent Crisis Isn’t Pump—It’s Under Your Hood
A looming base oil shortage threatens routine oil changes as global supply tightens. The ‘imminent’ crisis isn’t pump...
Medical's General Counsel Sells: Smiths Integration Update
When high-level insiders transact, it sparks questions. This article explains what medical's general counsel sells si...
Limoneira (LMNR) 2026 Earnings Preview: Key Drivers
Investors are watching limoneira (lmnr) 2026 earnings for clues on citrus demand, real estate activity, and cost mana...
Despite Production Guidance, Lucid Faces a Long Road Ahead
Lucid has set a production target, but many investors wonder if the pace will match the plan. This deep dive explains...
Realty Income Secures Another Billion-Dollar Partnership
Realty Income just announced a $1 billion joint venture with Apollo, expanding its real estate platform and preservin...
Super Micro Computer's Sales Surge: Why I Stay Way From the Stock
A spike in revenue can grab headlines, but it rarely tells the full investment story. Here’s why super micro computer...
Microsoft Distancing Itself From OpenAI Could Help Investors
As AI accelerates, the Microsoft-OpenAI relationship faces shifts. This piece explains why microsoft distancing itsel...
AbbVie Reports Promising Clinical Updates, Dividend Outlook
AbbVie’s latest clinical progress could shape its dividend future. This guide breaks down what promising results mean...
Teva's Biosimilar Boom Just Beginnings: Is It Time to Buy?
Teva is turning the corner with a growing biosimilars roster and improving margins. This article examines whether tev...
Should Avoid Pfizer? Here's the Key Risk to Watch Today
Pfizer has been a market mover, but recent shifts in demand and patent timelines raise concerns. This guide breaks do...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status